I'd suggest putting together a fact binder with the clinical trials.gov info, the MOA poster, the contact name of the NP at DF, the CTIX website, print any of the pre-clinical information. The key is to talk facts and not speculation. Anybody in pharma will naturally be skeptical especially since CTIX is a potential competitior and is in phase one. At the end of the meeting, ask for action, e.g. ask him to read the information and ask him his assessment of it at a later date. Close him for that action.
